Advertisement

Bharat Biotech begins COVAXIN supply to 14 states based on central government's guidance

Follow The Hawk on Google News+ Follow

Advertisement


Hyderabad: Bharat Biotech has started direct supplies of its Covid-19 vaccine Covaxin to 14 states.

The states are Andhra Pradesh, Assam, Chhattisgarh, Delhi, Gujarat, Jammu & Kashmir, Jharkhand, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Telangana, Uttar Pradesh and West Bengal.

Advertisement

The Hyderabad-based company said it started the supplies based on the allocations received by the Government of India.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

"Requests have been received from other states, & will be processed for distribution based on availability of stocks 24x7," tweeted Bharat Biotech co-founder and Joint Managing Director Suchitra Ella.

The company, however, has not come out with details of the supplies like the number of doses supplied to the states.

Advertisement

Bharat Biotech on April 24 announced pricing for Covaxin. It fixed the price of Covaxin at ₹600 per dose for state governments.

Also read'Fatty liver-free campaign' in Ranchi from Nov 23, MoS Sanjay Seth to take lead

However, it later slashed the price to ₹400. This came after Serum Institute of India (SII) cut the price of Covishield to ₹300 from ₹400 earlier.

The two vaccine makers slashed the prices after the central government reportedly made a request to them amid the row over different pricing for the central and state governments.

For private hospitals, Bharat Biotech fixed the price at ₹1,200 per dose. This is twice the cost fixed for Covishield.

For exports, Bharat Biotech has priced India's first indigenous Covid vaccine at $15-$20 (₹1,125-1,500).

Ever since the launch of Covid vaccination programme in India, Bharat Biotech and SII have been supplying their vaccines to the Centre at ₹150 per dose.

While Bharat Biotech is likely to continue the supplies to the Centre at the same price, SII is seeking to revise this to ₹400.

Both Bharat Biotech and SII have announced that they are reserving 50 per cent of their production capacities for supplies to the central government.

—IANS

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST